1. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis
Garry J. Handelman, Mary F. Walter, Rohini Adhikarla, Jonathan Gross, Gerard E. Dallal, Nathan W. Levin, Jeffrey B. Blumberg 
Kidney International 
Volume 59, Issue 5, Pages (May 2001)
DOI: /j x
Copyright © 2001 International Society of Nephrology Terms and Conditions

2. Figure 1
Pathway for enzymatic synthesis of prostaglandin F2α and for free-radical initiated synthesis of F2-isoprostanes.
Kidney International  , DOI: ( /j x)
Copyright © 2001 International Society of Nephrology Terms and Conditions

3. Figure 2
Levels of esterified F2-isoprostanes in end-stage renal disease (ESRD) patients and controls. The difference is significant (P < 0.001).
Kidney International  , DOI: ( /j x)
Copyright © 2001 International Society of Nephrology Terms and Conditions

4. Figure 3
Levels of C-reactive protein (CRP) in ESRD patients and controls. The difference is significant (P < 0.02).
Kidney International  , DOI: ( /j x)
Copyright © 2001 International Society of Nephrology Terms and Conditions

5. Figure 4
Plasma CRP and F2-isoprostanes in hemodialysis patients, plotted on logarithmic axes for each variable.
Kidney International  , DOI: ( /j x)
Copyright © 2001 International Society of Nephrology Terms and Conditions

6. Figure 5
Effects of a single dialysis session on plasma esterified F2-isoprostanes in 10 ESRD patients. F2-isoprostanes in plasma from each patient were measured before and after the HD session.
Kidney International  , DOI: ( /j x)
Copyright © 2001 International Society of Nephrology Terms and Conditions